Takara Bio (FRA:TF2) Other Current Payables: €7.3 Mil (As of Mar. 2026)


FRA:TF2 Takara Bio Inc FRA:TF2
50 GF Score
Price €5.95
GF Value €4.47
! 6 Warning Signs
View Full Analysis

What is Takara Bio Other Current Payables?

Takara Bio FRA:TF2 50 Other Current Payables is €7.3 Mil as of Mar. 2026. GuruFocus rates FRA:TF2 with a GF Score™ of 50/100 and a GF Value™ of €4.47. The stock has 6 warning signs investors should review.

Takara Bio's Other Current Payables for the quarter that ended in Mar. 2026 was €7.3 Mil.

Takara Bio's quarterly Other Current Payables declined from Sep. 2025 (€0.0 Mil) to Dec. 2025 (€-0.0 Mil) but then increased from Dec. 2025 (€-0.0 Mil) to Mar. 2026 (€7.3 Mil).

Takara Bio's annual Other Current Payables declined from Mar. 2024 (€11.8 Mil) to Mar. 2025 (€11.0 Mil) and declined from Mar. 2025 (€11.0 Mil) to Mar. 2026 (€7.3 Mil).

Takara Bio Other Current Payables Related Terms

Takara Bio Other Current Payables Historical Data

* Premium members only.

The historical data trend for Takara Bio's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio Other Current Payables Chart

Takara Bio Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.02 30.78 11.78 10.99 7.31

Takara Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.99 -0.00 0.00 -0.00 7.31
FRA:TF2
50GF Score
Takara Bio Inc FRA:TF2
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takara Bio Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €7.3 Mil mean?
Takara Bio (FRA:TF2) has a Other Current Payables of €7.3 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Takara Bio and its competitors.
Is Takara Bio's Other Current Payables too high?
Takara Bio's current Other Current Payables is €7.3 Mil. Overall, Takara Bio has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Other Current Payables compare to VRTX and REGN?
Takara Bio's Other Current Payables of €7.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Takara Bio and its competitors. Takara Bio's current Other Current Payables is €7.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Takara Bio (FRA:TF2) has a current Other Current Payables of €7.3 Mil. The stock's GF Value™ is €4.47, compared to a current price of €5.95 — trading 33.1% above its estimated fair value. The current Other Current Payables is €7.3 Mil. Takara Bio's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Other Current Payables is €7.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takara Bio (FRA:TF2) Overvalued in 2026?

Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued. The current stock price of €5.95 is trading 33.1% above its estimated GF Value™ of €4.47.

Key valuation signals for FRA:TF2:

  • Other Current Payables: €7.3 Mil
  • GF Value™: €4.47 vs. price of €5.95 (33.1% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takara Bio Business Description

Other Exchanges 4974:Japan
Address Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
50GF Score

Get the complete analysis for FRA:TF2

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.95
Price
€4.47
GF Value